GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Diet drug boom weighs heavily on state budgets
The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...
Patients on Ozempic report ‘waking up blind’ in as little as a day after using jab
PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...
Blockbuster weight-loss drugs flood grey market, used without supervision: ‘This trend is triggering paralysis of gut,’ warn doctors
Tirzepatide, found in Mounjaro and Zepbound, mimics both GIP and GLP-1 hormones to activate insulin production. Semaglutide, ...
News244d
Which of the breakthrough weight-loss medicines can you get in SA?
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...